Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

PROVIDER: PRJNA1166965 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30834300_1.fastq.gz	Fastqsanger.gz
	SRR30834300_2.fastq.gz	Fastqsanger.gz
	SRR30834301_1.fastq.gz	Fastqsanger.gz
	SRR30834301_2.fastq.gz	Fastqsanger.gz
	SRR30834302_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 178

Similar Datasets

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

Characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

Project description:We have generated a collection of patient-derived xenograft (PDX) tumor models and characterized them at the molecular level to facilitate precision oncology. Surgically resected HCC specimens were subcutaneously implanted in immunodeficient mice. Resulting xenografts were serially implanted to establish transplantable PDX models, which were sequentially subject to whole exome sequencing (WES), gene expression array, genome-wide human single nucleotide polymorphism (SNP) array 6.0, and serum a–fetoprotein (AFP) detection assay. The feasibility as a preclinical model was validated by efficacy studies using a standard-of-care (SOC) and a targeted agent, respectively.

2014-03-13 | E-GEOD-55828 | biostudies-arrayexpress

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived micro-organospheres (MOS) enable clinical precision oncology

| PRJNA763787 | ENA

Project description:Patient-derived micro-organospheres (MOS) enable clinical precision oncology

| PRJNA762992 | ENA

Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

Project description:Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

| PRJNA554654 | ENA

gut metagenome

Project description:Bacterial microbiota in biliary tract cancer patient

| PRJDB11180 | ENA

Characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

Project description:We have generated a collection of patient-derived xenograft (PDX) tumor models and characterized them at the molecular level to facilitate precision oncology.

2014-03-13 | GSE55828 | GEO

Tumor evolution and drug response in patient-derived organoid models of bladder cancer

Project description:Bladder cancer is the fifth most prevalent cancer in the U.S., yet is understudied and relatively lacking in suitable models. Here we describe a biobank of patient-derived organoid lines that recapitulates the spectrum of human bladder cancer at the histopathological and molecular levels. Organoid lines can be established efficiently from patient biopsies, including from patients before and after disease recurrence, and are interconvertible with orthotopic xenografts. Notably, these organoid lines often retain tumor heterogeneity and exhibit changes in their mutational profiles that are consistent with tumor evolution in culture. Analyses of drug response using bladder tumor organoids show partial correlations with mutational profiles as well as changes associated with treatment resistance, and specific responses can be validated using xenografts in vivo. Overall, our studies indicate that patient-derived bladder tumor organoids represent a model system for studying tumor evolution and treatment response in the context of precision cancer medicine.

2018-04-09 | GSE103990 | GEO

Homo sapiens

Project description:Patient-derived Human Breast Cancer Xenografts

| PRJNA197288 | ENA

National Cancer Institute - Patient Derived Model Repository

Project description:Patient-derived tumor xenografts developed by the National Cancer Institute's Patient Derived Model Repository (PDMR)

| PRJEB37099 | ENA